Page 4

Recently published articles about Difficult to Treat Depression

PCC
Neurobiological Correlates of Psilocybin Response in MDD
Systematic Review

May 23, 2023

Transient functional brain changes with psilocybin therapy resemble the “brain reset” phenomenon and may serve as the putative predictors of psilocybin antidepressant response.
, , , et al
PCC
L-Methylfolate as Adjunctive Therapy in MDD Treatment
Narrative Review

May 9, 2023

l-Methylfolate is effective as an adjunctive treatment in MDD and may especially benefit patients with higher body mass index and inflammation.
, ,
l-Methylfolate as Adjunctive Therapy in the Treatment of Major Depressive Disorder">
JCP
rTMS for Treatment-Resistant Depression: Mismatch of Evidence and Insurance Coverage Policies
Commentary

April 26, 2023

The authors argue that insurance companies’ prior authorization process overly restricts access to rTMS, which has proven effectiveness for TRD.
, , , et al
JCP
Pharmacotherapy and Ketamine Assisted Psychotherapy for Treatment-Resistant Depression
Cross Talk: Case Conferences From MGH

April 5, 2023

A 61-year-old patient with TRD and a history of self-criticism sought ketamine assisted psychotherapy. Experts from diverse therapeutic perspectives discuss this intriguing case.
, , , et al
PCC
REL-1017 Effects on Cognition in MDD
Original Research

February 14, 2023

REL-1017 improved subjective measures of cognitive impairment, in addition to improving total MADRS and SDQ scores.
, , , et al
JCP
Ketamine vs Esketamine for TRD
Original Research

February 1, 2023

Are ketamine and esketamine equally efficacious? This observational study compares the efficacy of subanesthetic intravenous ketamine with that of intranasal esketamine for treatment-resistant depression in a real-world clinical setting.
, , , et al
PCC
Impairment of Sexual Desire in Treatment-Resistant Depression
Original Research

November 22, 2022

Patients with treatment-resistant depression had a high prevalence of sexual desire impairment, which was associated with male sex and higher depressive symptom severity.
, , , et al
news

November 4, 2022

Breakthrough research explores ketamine as a treatment for depression. Patrick A. Oliver, MD and Albert J. Arias, MD, MS share the efficacy results of ketamine for treatment-resistant depression (TRD),...
JCP
Combined Ketamine and Monoamine Oxidase Inhibitors
Systematic Review

October 24, 2022

Little is known about actual side effects of augmentation of ketamine to monoamine oxidase inhibitors (MAOIs). This systematic review and cases series evaluated symptoms of serotonin syndrome and hypertension...
, , , et al
JCP
Acceptability of Second-Line Antidepressant Medications
Original Research

October 17, 2022

Second-line antidepressant options were ranked according to acceptability (efficacy and tolerability), using data from the French health system.
, , , et al
JCP
Esketamine Nasal Spray and Adverse Events Over Time
Original Research

September 19, 2022

This study looked at the occurrence and severity of adverse events over time with esketamine nasal spray in MDD patients also receiving an oral antidepressant.
, , , et al
JCP
Intravenous Ketamine for Treatment-Resistant Depression
Original Research

September 12, 2022

The clinical effectiveness of ketamine for suicidal ideation and treatment-resistant depression outside of controlled clinical trials is unclear. This article reports clinical outcomes of a large cohort treated with...
, , , et al

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe